OSE Immunotherapeutics SA (EPA:OSE)

OSE Immunotherapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	37.45	-23	-17.76	-16.85	-16.56
Depreciation & Amortization	6.26	1.17	3.54	2.66	0.73
Other Amortization	-	2.36	-	-	-
Stock-Based Compensation	2.09	1.75	2.73	2.94	1.79
Other Operating Activities	0.67	-0.98	-3.38	0.64	-2.32
Change in Accounts Receivable	-3.16	-	-	-	-
Change in Accounts Payable	1.57	-	-	-	-
Change in Income Taxes	2.62	-0.22	-0.24	-0.33	-
Change in Other Net Operating Assets	0.94	-0.84	-3.14	1.03	-3.19
Operating Cash Flow	48.44	-19.76	-18.25	-9.92	-19.55
Capital Expenditures	-0.08	-0.02	-0.27	-0.47	-0.21
Investment in Securities	-46.57	0	-	-	-
Other Investing Activities	-	-0.49	0.3	-0.36	-0.29
Investing Cash Flow	-46.91	-0.51	0.03	-0.83	-0.5
Long-Term Debt Issued	2.11	5.02	12.06	15.28	6.96
Long-Term Debt Repaid	-6.25	-3.36	-1.8	-0.59	-0.81
Net Debt Issued (Repaid)	-4.15	1.67	10.26	14.69	6.15
Issuance of Common Stock	1.16	11.66	-	0.27	18.63
Other Financing Activities	-0.47	-	0.01	-	-1.2
Financing Cash Flow	-3.46	13.32	10.27	14.96	23.58
Miscellaneous Cash Flow Adjustments	-	-0	-	-	-
Net Cash Flow	-1.93	-6.95	-7.96	4.21	3.53
Free Cash Flow	48.36	-19.78	-18.53	-10.39	-19.76
Free Cash Flow Margin	57.97%	-888.19%	-101.22%	-39.50%	-189.65%
Free Cash Flow Per Share	1.91	-1.01	-1.00	-0.57	-1.27
Cash Income Tax Paid	2.62	-	-	-	0.05
Levered Free Cash Flow	-7.75	-11.18	-9.07	-4.21	-12.47
Unlevered Free Cash Flow	-4.26	-9.8	-8.21	-3.69	-12.3
Change in Net Working Capital	40.49	0.98	3.06	-0.75	3.23

Updated Sep 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.